Merck will acquire EyeBio through a subsidiary in an agreement potentially valued at $3 billion, according to a press release.
The acquisition, unanimously approved by the EyeBio board of directors, will expand Merck’s presence in ophthalmology and augment its pipeline.
Merck will acquire all outstanding shares of EyeBio for up to $3 billion, including an upfront cash payment of $1.3 billion and a potential $1.7 billion in “developmental, regulatory and commercial milestone payments,” according to the release.
The acquisition includes EyeBio’s lead candidate Restoret